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Transparency of reporting is an accepted surrogate for the
methodological quality of randomised–controlled trials. A
bulk of literature has been published investigating the internal
validity of studies using tools and checklists comprising
transparency items for analysis of the studies’ publications.
That is exactly what we have done in our European Review of
Aging and Physical Activity (EURAPA) paper published in
2006 [1]. Our analysis was not a Cochrane review but
rather a critical appraisal of the transparency of
published data of hip protector studies. We exemplarily
focused on two papers that the reviewers of the
Cochrane review on hip protector [2] have rated as
having very good methodological quality and which
received the largest weight in the meta-analysis of
institutional setting studies. One of these studies was the
paper by O’Halloran et al. [3] published in 2004.
Therefore, a contact of the authors would have been
unusual, not adequate and not required according to ethical
guidelines. O’Halloran’s criticism that we should have
contacted him to receive the important information not
accessible within and via the original publication is
therefore inappropriate.
The aim of our analysis [1] was to confirm that the
empirically proven criteria of internal validity of randomised–
controlled trials as included in critical appraisal proce-
dures and tools do not cover the question if the reported
intervention was carefully prepared and optimally
implemented. However, careful preparation is exception-
ally important in complex interventions like education
programmes. The Medical Research Council [4] has
suggested a framework on the development of complex
interventions including exploration of a theory, identifying
and modelling of components of the intervention and their
underlying mechanism, feasibility and acceptability testing
within an exploratory trial. Since many reports of complex
interventions conclude that there is a lack of efficacy of the
intervention programme, it is often impossible for the reader
to judge if the intervention had really been ineffective or if in
fact it had not been sufficiently prepared or optimally
implemented. In our paper, we demonstrated that the critical
appraisal procedure used in the Cochrane review on hip
protectors [2] did not address these issues sufficiently. We
informed the principal Cochrane reviewer, Martyn J Parker,
about our findings.
It is not true as claimed by O’Halloran that transparency
must inevitably be heavily affected by word limitation of
papers as requested by the journal. If an author judges the
information as indispensable, he or she would decide to
insert this piece of information guided by triage.
Obviously, O’Halloran misunderstood the sentence inserted
in our EURAPA paper “Access to the education programme is
not possible neither by further references nor authors’ offer to
contact them”. The paper of O’Halloran did not comprise a
reference on the published programme. Nevertheless, the
authors could have offered to make the material available to
the public by a sentence like: “The education programme is
available from the authors on request”.
We feel that O’Halloran’s letter supports the critical issues
raised in our manuscript [1] since the author verifies the lack
of transparency in reporting of his original hip protector
study. Better reporting will help readers critically appraise the
internal validity and to interpret trial results and general-
isability. Therefore, we would like to encourage any
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methodological effort to increase the transparency of report-
ing of complex interventions. It might be time to think about
an extension of the CONSORT statement with regard to
complex interventions.
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